Rationale for the concept of combined initial therapy im type 2 diabetes mellitus
https://doi.org/10.14341/DM13484
Abstract
Glycemic targets remain a challenge for most patients with type 2 diabetes (T2D). In many cases, this is due to the patient’s non-compliance with the treatment regimen, insufficient self-monitoring, and delayed intensification of therapy. However, these challenges have been present for many years, and even new classes of antidiabetic drugs have not significantly changed the proportion of individuals with optimal target glycated hemoglobin levels of < 7%. Usually the treatment strategy in T2D patients requires gradual intensification from monotherapy to combination therapy, and afterwards to insulin. However, despite the high proportion of patients who do not achieve target glycemic levels, most patients receive only one medication for the first 5-8 years of treatment. Therefore, there is a need to start T2D therapy with combination of drugs instead of monotherapy. This article provides a rationale for this transition and suggests strategies for implementing it.
About the Author
E. A. Shestakova
Russian Medical Academy of Continuous Professional Education; Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Ekaterina A. Shestakova, MD, PhD, Associate Professor, сhief research associate
Moscow
Competing Interests:
none
References
1. Dedov II, Shestakova MV, Mayorov AY, et al. Clinical guidelines. Type 2 diabetes mellitus in adults. Moscow: Russian Association of Endocrinologists; 2022. (In Russ.)
2. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S183–S215. doi: https://doi.org/10.2337/dc26-S009
3. Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiology and key clinical and therapeutic indicators of diabetes mellitus in Russian Federation according to the World Health Organization’s strategy goals. Diabetes mellitus. 2025;28(1):4–17. (In Russ.) doi: https://doi.org/10.14341/DM13292
4. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023;26(2):104–123. (In Russ.) doi: https://doi.org/10.14341/DM13035
5. Dedov I, Shestakova M, Sukhareva O, et al. Standards of Specialized Diabetes Care / Edited by Dedov II, Shestakova MV, Sukhareva OY. 12th Edition. Diabetes mellitus. 2025;28(5S):1–175. (In Russ.) doi: https://doi.org/10.14341/DM20255S
6. Matthews DR, Paldánius PM, Proot P, et al; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529. doi: https://doi.org/10.1016/S0140-6736(19)32131-2
7. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. doi: https://doi.org/10.1056/NEJMoa012512
8. Cahn A, Wiviott SD, Mosenzon O, et al. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care. 2022;45(4):938–946. doi: https://doi.org/10.2337/dc21-1744
9. Raz I, Mosenzon O, Bonaca MP, et al. DECLARE-TIMI 58: Participants’ baseline characteristics. Diabetes Obes Metab. 2018;20(5):1102–1110. doi: https://doi.org/10.1111/dom.13217
10. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi: https://doi.org/10.1093/eurheartj/ehz486
11. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–4140. doi: https://doi.org/10.1093/eurheartj/ehad192
12. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1–S127. doi: https://doi.org/10.1016/j.kint.2022.06.008
13. Harrington JL, de Albuquerque Rocha N, Patel KV, et al. Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. Curr Diab Rep. 2018;18(9):64. doi: https://doi.org/10.1007/s11892-018-1035-z
14. Babenko AY, Mosikian AA, Makarenko IE, et al. Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial. Diabetes mellitus. 2018;21(4):241–254. (In Russ.)] doi: https://doi.org/10.14341/DM9586
15. Kim G, Lim S, Kwon HS, et al. Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with openlabel extension (the EVERGREEN study). Diabetes Obes Metab. 2020;22(9):1527–1536. doi: https://doi.org/10.1111/dom.14061
16. Park SH, Jeong HE, Oh IS, et al. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study. Diabetes Obes Metab. 2021;23(6):1232–1241. doi: https://doi.org/10.1111/dom.14330
17. Moon JS, Park IR, Kim HJ, et al. Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension. Diabetes Metab J. 2023;47(6):808–817. doi: https://doi.org/10.4093/dmj.2022.0387
18. Han E, Huh JH, Lee EY, et al. Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial. Diabetes Obes Metab. 2022;24(4):752–756. doi: https://doi.org/10.1111/dom.14623
Supplementary files
|
|
1. Рисунок 1. Предлагаемая тактика выбора сахароснижающей терапии. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(481KB)
|
Indexing metadata ▾ | |
Review
For citations:
Shestakova E.A. Rationale for the concept of combined initial therapy im type 2 diabetes mellitus. Diabetes mellitus. 2026;29(3):290-295. (In Russ.) https://doi.org/10.14341/DM13484
Views:
63
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
